Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
Journal of Medical Virology · 2024-01 · 96 (1)
DOI: 10.1002/jmv.29333 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, online erschienen am 04.01.2024. Verfasst von Matthew S Durstenfeld und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology at ZSFG, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA. Hauptthemen laut MEDLINE: Post-Acute COVID-19 Syndrome, COVID-19. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, Patient-Centered Outcomes Research Institute.
Abstract (Originalsprache)
Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of treatment during acute infection on risk of Long COVID is unknown. We hypothesized that nirmatrelvir treatment during acute SARS‐CoV‐2 infection reduces risk of developing Long COVID and rebound after treatment is associated with Long COVID. We conducted an observational cohort study within the Covid Citizen Science (CCS) study, an online cohort study with over 100 000 participants. We included vaccinated, nonhospitalized, nonpregnant individuals who reported their first SARS‐CoV‐2 positive test March–August 2022. Oral nirmatrelvir/ritonavir treatment was ascertained during acute SARS‐CoV‐2 infection. Patient‐reported Long COVID symptoms, symptom rebound and test‐positivity rebound were asked on subsequent surveys at least 3 months after SARS‐CoV‐2 infection. A total of 4684 individuals met the eligibility criteria, of whom 988 (21.1%) were treated and 3696 (78.9%) were untreated; 353/988 (35.7%) treated and 1258/3696 (34.0%) untreated responded to the Long COVID survey ( n = 1611). Among 1611 participants, median age was 55 years and 66% were female. At 5.4 ± 1.3 months after infection, nirmatrelvir treatment was not associated with subsequent Long COVID symptoms (odds ratio [OR]: 1.15; 95% confidence interval [CI]: 0.80–1.64; p = 0.45). Among 666 treated who answered rebound questions, rebound symptoms or test positivity were not associated with Long COVID symptoms (OR: 1.34; 95% CI: 0.74–2.41; p = 0.33). Within this cohort of vaccinated, nonhospitalized individuals, oral nirmatrelvir treatment during acute SARS‐CoV‐2 infection and rebound after nirmatrelvir treatment were not associated with Long COVID symptoms more than 90 days after infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology at ZSFG, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
- Division of HIV, Infectious Disease, & Global Medicine, UCSF, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
- Department of Epidemiology & Population Health, Albert Einstein College of Medicine, New York City, New York, USA.
- Louisiana Public Health Institute, New Orleans, Louisiana, USA.
- Department of Experimental Medicine, UCSF, San Francisco, California, USA.
ORCID-Profile: Matthew S Durstenfeld
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- Patient-Centered Outcomes Research Institute
- National Institute of Biomedical Imaging and Bioengineering
- Bill and Melinda Gates Foundation
- National Heart, Lung, and Blood Institute
Zitieren
APA
Durstenfeld, M. S., Peluso, M. J., Lin, F., Peyser, N. D., Isasi, C., Carton, T. W., Henrich, T. J., Deeks, S. G., Olgin, J. E., Pletcher, M. J., Beatty, A. L., Marcus, G. M., & Hsue, P. Y. (2024). Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study. Journal of Medical Virology, 96(1). https://doi.org/10.1002/jmv.29333
Vancouver
Durstenfeld MS, Peluso MJ, Lin F, Peyser ND, Isasi C, Carton TW, et al. Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study. Journal of Medical Virology. 2024;96(1). doi:10.1002/jmv.29333
BibTeX
@article{Durstenfeld2024,
author = {Durstenfeld, Matthew S and Peluso, Michael J and Lin, Feng and Peyser, Noah D and Isasi, Carmen and Carton, Thomas W and Henrich, Timothy J and Deeks, Steven G and Olgin, Jeffrey E and Pletcher, Mark J and Beatty, Alexis L and Marcus, Gregory M and Hsue, Priscilla Y},
title = {Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study},
journal = {Journal of Medical Virology},
year = {2024},
volume = {96},
number = {1},
doi = {10.1002/jmv.29333}
}
EUVIMED